Sample6 Technologies, a Boston-based developer of a so-called bacterial monitoring platform, has appointed Tim Curran as CEO. Curran was previously CEO of Vela Systems, which sold to Autodesk last year; he was also CEO of Eleven Technologies, acquired by Trimble Navigation in 2006. Sample6 is backed by Flybridge Capital Partners, Chevron Tech Ventures, The Kraft Group, Founder Collective and Boston University, among others.
Sample6 Technologies, the developer of the world’s fist synthetic biology-based, “enrichment-free” bacterial monitoring platform, has appointed Tim Curran as Chief Executive Officer. Curran has an over 20 year record of success leading technology companies, including as CEO of Vela Systems, which he led to an acquisition by Autodesk in 2012. Previously, he was CEO of Eleven Technologies which was acquired by Trimble Navigation in 2006.
“We could not have found a better person for the position,” said Micah Rosenbloom, Sample6’s founding CEO who will remain on the company’s board and active in the product and commercial development. “Tim has that rare combination of start-up DNA coupled with a proven ability to bring breakthrough technologies to traditional industries from construction to food.” Rosenbloom continued, “We have the opportunity to commercialize the first ‘smoke detector’ for pathogens and to improve the health and safety of the global consumer.”
Tim Curran: An Established High-Tech and Enterprise Executive
With more than 20 years of executive management and leadership experience bringing high-tech solutions to enterprises, Curran has served in a variety of roles with globally recognized business and technology brands.
Most recently as CEO of Vela Systems, Curran led the company through development and commercialization of a revolutionary quality management system for the construction industry. Vela was the first to bring a Cloud platform and iPad devices to the construction industry. Over half of the Top 50 US construction companies are Vela customers. The company had customers in 14 countries and was growing 100% annually when acquired by Autodesk in June 2012.
Previously, Curran served as CEO of Eleven Technologies, a next generation mobile field management solution for the food and beverage industry with customers including Coca-Cola, P&G and Pepperidge Farms, which was acquired by Trimble Navigation in 2006. Curran was previously head of Sales & Marketing for I-many, whose customers included Pepsico, Conagra and Kellogg. I-many grew from $3M to $60M in revenue during his tenure and went public in 2000. He started his career in technology development and implementation at Accenture and EMC.
“Sample6 is on the cusp of delivering game-changing pathogen detection capabilities to the food industry, from farm to consumer,” said Curran. “I am thrilled to have the opportunity to join a world-class synthetic biology and product development organization to lead the company to commercial success. Sample6 delivers tremendous supply chain and brand protection value to businesses while at the same time driving down food safety related illness and deaths. The chance to build a fantastic business combined with making a real difference in health and safety is a rare career opportunity. ”
Sample6’s novel environmental pathogen monitoring platform is currently being piloted at 7 major food companies and has applications in food processing, retail, healthcare, and any place where bacterial contamination poses a risk to consumers. Unlike other technologies in the marketplace, Sample6 can monitor the growth of pathogens, alert its users and enable them to take action before problems occur.
“Sample 6 is leading a revolution in pathogen detection by innovating at the intersection of biotech, sensors and software. Tim’s background is ideal for driving the company forward,” said Jon Karlen, general partner at Flybridge Capital Partners, one of Sample6’s investors and board members.
About Sample6 Technologies
Sample6 Technologies is the developer of the world’s first “enrichment-free” diagnostics platform powered by synthetic biology. It is backed by top tier venture capitalists including Flybridge Capital Partners, Chevron Tech Ventures, The Kraft Group, Founder Collective and Boston University. The company is based in Boston, MA.